Recent News

• 10.16.2026 - Biomerica Reports First Quarter Fiscal 2027 Financial Results
• 09.01.2026 - Biomerica Reports Fiscal 2026 Year-End Financial Results
• 08.27.2026 - Biomerica Announces $2.23 Million Financing
• 05.28.2026 - Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
• 04.29.2026 - Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
• 04.16.2026 - Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
• 04.14.2026 - Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
• 04.13.2026 - Biomerica Reports Third Quarter Fiscal 2026 Financial Results
• 03.18.2026 - Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
• 03.05.2026 - Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Recent Filings

• 10.16.2026 - DEF 14A Other definitive proxy statements
• 10.15.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.15.2026 - 8-K Current report
• 10.07.2026 - EFFECT Notice of Effectiveness
• 10.07.2026 - EFFECT Notice of Effectiveness
• 09.28.2026 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 09.24.2026 - S-3 Registration statement under Securities Act of 1933
• 09.24.2026 - S-3 Registration statement under Securities Act of 1933
• 09.10.2026 - 3 Initial statement of beneficial ownership of securities
• 09.08.2026 - 3 Initial statement of beneficial ownership of securities